OakChart

Halozyme Therapeutics Inc

HALOHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 10:12 AM ET

100.43-2.55 (-2.48%)
2026-11-11 16:12 CET
Market cap
11,740.75 USD m
Revenue, TTM
1,802.45 USD m
Net income, TTM
485.42 USD m
Free cash flow, TTM
885.88 USD m
EPS diluted, TTM
3.93
P/E
25.56
Compare

Price

HALO against its 20, 50 and 200-day averages
2050200beatmiss
60.0080.00100.00120.005.1M10.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HALOclose 100.4320-day 121.7350-day 114.93200-day 85.15100.43

25.1% under 134.00 on 30 Oct 2026. Last 15 sessions, 35.0% high to low

Profile

HALO
52-week range, 54% of the way up
61.22134

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

IndexRUI
Employees423
IPOMar 12, 2004
Beta0.93
ATR, 14d4.78
Rel volume1.23
Short float12.10%
Insider own1.08%
Inst own109.82%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap11.45B
Enterprise Value13.63B
Income485.42M
Sales1.80B
Book/sh-0.48
Cash/sh9.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees423
IPOMar 12, 2004

Ratios

P/E25.56
Forward P/E9.72
PEG0.23
P/S6.35
P/B-
P/C10.66
P/FCF12.93
EV/EBITDA11.85
EV/Sales7.56
Quick Ratio3.60
Current Ratio3.88
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)3.93
EPS next Y10.34
EPS next Q2.57
EPS this Y108.61%
EPS next Y19.38%
EPS next 5Y42.30%
EPS past 3/5Y21.17% 22.89%
Sales past 3/5Y28.38% 39.16%
EPS Y/Y TTM-14.29%
Sales Y/Y TTM45.03%
EPS Q/Q40.67%
Sales Q/Q39.15%
EarningsNov 05 AMC
EPS/Sales Surpr.3.70% 0.27%

Ownership

Insider Own1.08%
Insider Trans-20.54%
Inst Own109.82%
Inst Trans-0.07%
ROA17.05%
ROE216.38%
ROIC16.80%
Gross Margin76.06%
Oper. Margin56.67%
Profit Margin26.93%
SMA20-17.50%
SMA50-12.61%
SMA20017.95%
Trades-

Technical

Shs Outstand113.94M
Shs Float112.78M
Short Float12.10%
Short Ratio6.01
Short Interest13.65M
52W High134.00 -25.05%
52W Low61.22 64.03%
Volatility6.85% 3.81%
ATR (14)4.78
RSI (14)26.89
Beta0.93
Rel Volume1.23
Avg Volume2.27M
Volume426,329

Performance

Perf Week-22.95%
Perf Month-8.38%
Perf Quarter-0.24%
Perf Half Y43.41%
Perf YTD49.23%
Perf Year43.21%
Perf 3Y169.61%
Perf 5Y160.38%
Perf 10Y698.33%
Recom2.09
Target Price119.89
Prev Close102.98
Price100.43
Change %-2.48%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
TodayDowngradeMMorgan StanleyOverweight → Equal-Weight$109+8.5%
Aug 07, 2026UpgradeLLeerink PartnersMarket Perform → Outperform$110+9.5%
Dec 04, 2025DowngradeGGoldmanNeutral → Sell$56-44.2%
Oct 14, 2025UpgradeLLeerink PartnersUnderperform → Market Perform$70-30.3%
Aug 06, 2025UpgradeMMorgan StanleyEqual-Weight → Overweight$75-25.3%
Jul 10, 2025ResumedGGoldmanNeutral$55-45.2%
May 14, 2025DowngradeMMorgan StanleyOverweight → Equal-Weight$62-38.3%
May 13, 2025DowngradeLLeerink PartnersMarket Perform → Underperform$47-53.2%
Oct 07, 2024DowngradeWWells FargoOverweight → Equal Weight$58 → $62-38.3%
Sep 19, 2024DowngradeJJP MorganOverweight → Neutral$52 → $57-43.2%

Peers

Mkt cap
TickerCompanyMkt cap
LGNDLigand Pharmaceuticals Inc6.34B
RPRXRoyalty Pharma plc39.73B
ASNDAscendis Pharma A/S16.99B
WSTWest Pharmaceutical Services Inc28.81B
ARGXArgen X SE ADR60.83B
ALKSAlkermes plc7.87B
EXELExelixis Inc17.11B
BMRNBiomarin Pharmaceutical Inc11.09B
CORTCorcept Therapeutics Inc8.24B
PCRXPacira BioSciences Inc1.46B

Insider trading

latest 14 of 93
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Torley HelenPRESIDENT AND CEOOct 06 '26Option Exercise18.4120,000368,200787,780Oct 08 07:56 PM
Torley HelenPRESIDENT AND CEOOct 07 '26Option Exercise18.4120,000368,200787,780Oct 08 07:56 PM
Torley HelenPRESIDENT AND CEOOct 08 '26Option Exercise18.4120,000368,200787,780Oct 08 07:56 PM
Torley HelenPRESIDENT AND CEOOct 07 '26Sale111.5520,0002,231,049767,780Oct 08 07:56 PM
Torley HelenPRESIDENT AND CEOOct 06 '26Sale109.5820,0002,191,543767,780Oct 08 07:56 PM
Torley HelenPRESIDENT AND CEOOct 08 '26Sale109.4020,0002,187,909767,780Oct 08 07:56 PM
Posard Matthew L.DirectorOct 01 '26Sale108.545,230567,66153,609Oct 02 04:38 PM
Posard Matthew L.DirectorSep 16 '26Sale107.7418,9962,046,58158,839Sep 17 05:19 PM
MATTHEW POSARDDirectorSep 16 '26Proposed Sale106.2534,2263,636,512Sep 16 04:41 PM
Torley HelenPRESIDENT AND CEOSep 09 '26Option Exercise18.4120,000368,200787,780Sep 11 08:35 PM
Torley HelenPRESIDENT AND CEOSep 11 '26Option Exercise18.4120,000368,200787,780Sep 11 08:35 PM
Torley HelenPRESIDENT AND CEOSep 10 '26Option Exercise18.4120,000368,200787,780Sep 11 08:35 PM
Torley HelenPRESIDENT AND CEOSep 09 '26Sale107.4320,0002,148,536767,780Sep 11 08:35 PM
Torley HelenPRESIDENT AND CEOSep 11 '26Sale107.2420,0002,144,856767,780Sep 11 08:35 PM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B
IBBiShares Biotechnology ETFAUM: 11.36B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B
IJKiShares S&P Mid-Cap 400 Growth ETFAUM: 10.46B

News

latest 14 of 206
  • Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 (PR Newswire) -15.72%
  • U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer (PR Newswire)
  • Halozyme Posts Record Royalties, A Third Guidance Raise And A European Win Against Merck, But The Raise Is Smaller And Growth Is Cooling (Earnings Whispers) -5.66%
  • Halozyme falls 6% as raised guidance fails to impress investors (Investing.com)
  • Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press)
  • Loading…
  • HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE (PR Newswire)
  • Halozyme Faces A Higher Bar As Royalty Cadence Tests Its Rally (Earnings Whispers)
  • How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs (Investor's Business Daily)
  • Halozyme to Report Third Quarter 2026 Financial and Operating Results (PR Newswire)
  • Top Research Reports for Mastercard, AstraZeneca & Sandisk (Zacks) +6.57%
  • Halozyme stock rises after winning injunction against Merck (Investing.com)
  • Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets (PR Newswire)
  • Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE Technology (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-052.3902.3052.010492.97491.637
2026Q22026-08-062.2801.7871.897481402.287
2026Q12026-05-111.6001.5451.221376.71358.66
2025Q42026-02-17-0.2402.198-1.203451.77435.715
2025Q32025-11-031.7201.6301.432354.26340.036
2025Q22025-08-051.5401.2681.330325.72285.916
2025Q12025-05-061.1100.9240.933264.86230.116
2024Q42025-02-181.2601.1581.062298.01285.746
2024Q32024-10-311.2700.9911.053290.08252.178
2024Q22024-08-060.9100.7390.722231.35204.948
2024Q12024-05-070.7900.6870.596195.88199.747
2023Q42024-02-200.8200.8250.652230.042316
2023Q32023-11-060.7500.7060.610216.03216.087
2023Q22023-08-080.7400.6300.560221.04199.955
2023Q12023-05-090.4700.3830.287162.14179.268
2022Q42023-02-210.4200.2990.416181.5192.057

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.500-0.441-0.501195.99198.85
2020FY0.9100.9260.913267.59265.21
2021FY2.7402.6832.743443.31443.24
2022FY1.4401.3171.438660.12671.79
2023FY2.7702.7702.098829.25830.53
2024FY4.2304.1283.4311,0151,003
2025FY4.1506.5542.5601,3971,394
2026FY-8.657--1,899
2027FY-10.335--2,181
2028FY-11.958--2,322
2029FY-10.657--2,177
2030FY-9.907--2,039

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06751551.44540574.32
2026Q4S2026-11-05710537.55507561.4
2026Q4S2026-11-02710537.55507561.4
2026Q4S2026-10-21710537.59507561.4
2026Q4S2026-10-13740537.59507561.4
2026Q4S2026-10-09740537.45506561.4
2026Q4S2026-10-07740537.46506561.4
2026Q4S2026-09-02730533.31506561.4
2026Q4S2026-09-01730533.31506561.4
2026Q4S2026-08-07730533.31506561.4
2026Q4S2026-07-26700521.59498.7559.7
2026Q4S2026-07-22710521.59498.7559.7
2026Q4S2026-07-21710522.04498.7559.7
2026Q4S2026-07-10810526.12498.7559.7

Estimate history

EPS, annual0.45-0.559-0.5010.9132.7431.4382.0983.4312.5583.9295
Period201720182019202020212022202320242025TTM
EPS, quarterly1.0531.0620.9331.331.432-1.2031.2211.8972.015
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual316.613151.862195.992267.594443.31660.116829.2531015.3241396.6111802.45
Period201720182019202020212022202320242025TTM
Sales, quarterly290.084298.008264.861325.719354.264451.767376.708480.999492.974
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual142.789144.725136.712135.03137.498135.154126.77123.138117.782113.936
Period201720182019202020212022202320242025MRQ
Shares, quarterly127.183123.138123.17117.621117.523117.782118.523114.042113.936
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,802.451,396.611,015.32829.25660.12443.31267.59195.99151.86
Cost of Goods Sold Incl. D&A431.57305.44230.47266.13182.4581.4143.3745.5510.14
Gross Profit1,370.881,091.17784.86563.12477.66361.90224.23150.45141.73
Selling, General and Administrative Excl. Other349.35274.88233.38225.54188.2386.0079.97187.10255.26
Research and Development112.9081.4979.0576.3666.6135.6734.24123.60194.45
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1,021.54816.29551.48337.57289.43275.90144.25-36.65-113.53
Interest Expense22.0518.1318.0918.7616.957.5320.3811.6318.04
Unusual Expense353.23352.760.00-13.2024.6120.96-30.96-
Net Income Before Taxes655.01466.88557.13348.33248.92248.52129.30-72.25-123.99
Income Taxes169.59149.99113.0466.7346.79-154.190.22-0.01-43.66
Consolidated Net Income485.42316.89444.09281.59202.13402.71129.09-72.24-80.33
Net Income From Continuing Operations485.42316.89444.09281.59202.13402.71129.09-72.24-80.33
Net Income485.42316.89444.09281.59202.13402.71129.09-72.24-80.33
EPS (Recurring)5.984.553.432.031.562.840.91-0.35-0.56
EPS (Basic, Before Extraordinaries)4.202.643.502.131.482.860.95-0.50-0.56
EPS (Diluted)3.932.563.432.101.442.740.91-0.50-0.56
EBITDA1,150.17904.34632.79422.43339.07278.90147.54-32.58-111.14
Non-Operating Income (Expense)8.7621.4723.7516.321.051.105.426.997.58
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense53.4940.7434.2728.930.0215.2012.5625.3928.20
Price To Earnings Ratio26.2126.2115.8219.7338.1914.6447.38--
Price To Sales Ratio7.515.976.095.9812.1213.3122.5813.0613.83
Gross Margin76.0678.1377.3067.9172.3681.6483.7976.7693.33
Operating Margin56.6758.4554.3240.7143.8562.2453.91-18.70-74.76
Net Margin26.9322.6943.7433.9630.6290.8448.24-36.86-52.90
Shares Outstanding113.94117.78123.14126.77135.15137.50135.03136.71144.72
Market Capitalization11,740.7511,740.756,082.724,882.347,693.625,661.055,773.672,598.152,114.88

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue492.97481.00376.71451.77354.26325.72264.86298.01
Cost of Goods Sold Incl. D&A111.99108.68108.75102.1573.0064.1266.1759.82
Gross Profit380.99372.32267.96349.62281.26261.60198.70238.19
Selling, General and Administrative Excl. Other86.0284.6683.4495.2263.3459.1657.1662.69
Research and Development27.7827.6625.5631.9017.2517.5414.8020.44
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income294.97287.65184.52254.40217.92202.44141.53175.50
Interest Expense6.045.595.514.914.304.394.534.54
Unusual Expense0.470.000.00352.760.000.000.000.00
Net Income Before Taxes290.63284.90180.33-100.85218.96204.94143.83178.21
Income Taxes43.5854.9930.2840.7443.7339.7825.7341.20
Consolidated Net Income247.05229.91150.05-141.59175.22165.16118.09137.01
Net Income From Continuing Operations247.05229.91150.05-141.59175.22165.16118.09137.01
Net Income247.05229.91150.05-141.59175.22165.16118.09137.01
EPS (Recurring)2.021.901.220.901.431.330.931.06
EPS (Basic, Before Extraordinaries)2.171.961.27-1.201.491.360.961.08
EPS (Diluted)2.011.901.22-1.201.431.330.931.06
EBITDA329.18321.67218.25281.08238.38222.90161.98195.92
Non-Operating Income (Expense)2.172.841.322.435.336.896.827.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.2713.9813.1413.099.619.618.439.05
Price To Earnings Ratio26.2128.1525.9414.1516.7513.8018.5915.82
Price To Sales Ratio7.515.705.265.677.225.487.456.07
Gross Margin77.2877.4071.1377.3979.3980.3175.0279.93
Operating Margin59.8359.8048.9856.3161.5162.1553.4458.89
Net Margin50.1147.8039.83-31.3449.4650.7144.5945.98
Shares Outstanding113.94114.04118.52117.78117.52117.62123.17123.14
Market Capitalization11,740.759,283.847,627.447,914.288,578.296,409.967,882.646,082.72

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments142.82596.07336.00362.79740.92368.01421.26354.53469.21
Short Term Receivables441.27308.45234.21231.0790.9797.7359.4430.0022.13
Inventories176.47141.86127.60100.1253.9160.7529.3622.625.15
Other Current Assets64.6438.9548.6145.0240.4828.2733.3720.6913.88
Total Current Assets825.211,085.34746.42739.01926.29554.76543.44427.85510.37
Net Property, Plant & Equipment82.1475.0374.9475.578.7910.5910.867.463.52
Total Investments and Advances2.601.600.000.500.500.500.500.500.50
Intangible Assets1,561.83818.65889.70955.700.000.000.00--
Deferred Tax Assets188.99104.264.3944.43155.43----
Other Assets53.5579.0017.8226.3013.4114.0711.084.435.55
Total Assets2,714.312,163.881,733.271,841.511,104.43579.92565.87440.25519.95
Short Term Debt Incl. Current Port. of LT Debt11.287.056.5813.3389.42397.2319.5491.5177.21
Accounts Payable20.9010.2511.8217.691.541.936.434.087.95
Income Tax Payable--0.96------
Other Current Liabilities144.92121.8093.1499.7626.1922.2359.6653.7846.17
Total Current Liabilities177.09139.10112.49130.79117.15421.3885.64149.36131.33
Long Term Debt2,165.921,529.451,531.441,492.77787.250.00383.0534.87125.14
Provision for Risks Charges0.000.000.0015.470.000.000.000.000.00
Deferred Tax Liabilities231.91100.41-------
Other Liabilities90.5731.115.5232.693.077.495.437.1355.11
Total Liabilities2,665.491,800.061,649.461,671.71907.48428.88474.11191.36311.58
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity48.81363.8283.81169.80196.95151.0591.77248.89208.37
Total Shareholders Equity48.81363.8283.81169.80196.95151.0591.77248.89208.37
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity48.81363.8283.81169.80196.95151.0591.77248.89208.37
Total Liabilities & Stockholders Equity2,714.312,163.881,733.271,841.511,104.43579.92565.87440.25519.95
Book Value Per Share0.412.950.661.261.431.120.671.721.46
Tangible Book Value Per Share-12.85-3.69-6.36-5.811.431.120.671.721.46
Full-Time Employees423350373393145136132281255
Price to Book Ratio-212.4113.4319.5979.3228.0738.1826.418.5139.83
Return on Assets12.9922.7915.7513.7247.8222.53-14.36-16.7316.12
Return on Equity153.59198.42222.07110.23231.44106.33-42.41-35.1471.60
Return on Invested Capital14.3123.4617.4312.1640.9285.46-15.21-28.3118.88
Quick Ratio3.666.785.504.887.451.176.002.713.85
Current Ratio4.667.806.645.657.911.326.352.863.89

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income485.42316.89444.09281.59202.13402.71129.09-72.24-80.33
Depreciation128.5888.0581.3184.8649.643.003.284.072.39
Other Funds (Non Cash)418.07398.2442.4126.2934.2945.4331.4533.2934.31
Funds from Operations1,014.49803.81568.34427.24326.06295.70163.82-34.88-43.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-116.23-152.26-89.28-38.67-85.953.74-108.37-50.54-5.87
Cash from Operating Activities898.27651.56479.06388.57240.11299.4455.45-85.42-49.50
Capital Expenditures-12.39-6.97-10.70-15.29-4.81-1.46-2.50-4.04-4.66
Net Assets From Acquisitions-1,013.74-1,013.740.000.00-999.120.000.000.00-
Sale of Fixed Assets and Businesses0.710.000.000.0026.010.001.080.00-
Purchase or Sale of Investments239.04474.89-252.03-81.61490.92-404.8379.78-1.517.16
Purchase of Investments-120.61-247.35-647.60-292.91-255.21-652.51-226.19-389.76-311.11
Sale Or Maturity of Investments359.64722.25395.57211.30746.13247.68305.97388.25318.27
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-786.38-545.81-262.72-96.91-487.00-406.2978.35-5.552.49
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-368.19-320.54-218.86-394.50-185.95-337.52-86.72-185.7713.72
Repurchase of Common Pref Stock-400.00-342.37-250.00-402.38-200.00-350.06-150.12-200.000.00
Sale of Common Pref Stock31.8121.8331.147.8814.0512.5463.3914.2213.72
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net867.49235.370.00-13.48548.32415.39-19.56338.99-77.52
Change in Long Term Debt867.49235.370.00-13.48548.32415.39-19.56338.99-77.52
Issuance of Long Term Debt2,936.941,465.060.000.001,064.90784.450.00447.070.00
Reduction of Long Term Debt-2,069.45-1,229.690.00-13.48-516.57-369.06-19.56-108.08-77.52
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.00--0.00-0.00
Cash from Financing Activities499.30-85.17-218.86-407.99362.3777.86-106.28153.22-63.80
Net Change in Cash611.1820.57-2.52-116.33115.48-28.9827.5262.24-110.80
Free Cash Flow885.88644.59468.37373.28235.30297.9852.95-89.46-54.16
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow15.2812.9413.2113.2934.0019.81114.11--
Deferred Taxes & Investment Tax Credit-0.630.5334.5140.01-155.430.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,074.39231.00318.62142.82701.96548.18
Short Term Receivables525.59455.83457.99441.27346.04316.34
Inventories132.61137.13155.47176.47185.80181.50
Other Current Assets114.14109.0670.9664.6494.9576.65
Total Current Assets1,846.73933.021,003.04825.211,328.751,122.67
Net Property, Plant & Equipment82.2984.2782.2382.1471.4271.52
Total Investments and Advances6.862.152.562.600.000.00
Intangible Assets1,474.661,504.171,534.281,561.83765.37783.13
Deferred Tax Assets---188.990.0020.21
Other Assets62.8153.7950.6253.5555.7056.37
Total Assets3,473.352,577.412,672.722,714.312,221.232,053.90
Short Term Debt Incl. Current Port. of LT Debt305.61208.97208.7411.28710.680.00
Accounts Payable33.5523.6114.1020.9015.3618.69
Other Current Liabilities136.93111.86140.37144.92111.18115.59
Total Current Liabilities476.09344.44363.21177.09837.23134.28
Long Term Debt2,944.691,937.681,935.902,165.92800.071,509.10
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities6.3449.0647.53231.918.22-
Other Liabilities101.47102.68106.4590.5771.8077.77
Total Liabilities3,528.592,433.862,453.082,665.491,717.321,721.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-55.24143.54219.6448.81503.92332.75
Total Shareholders Equity-55.24143.54219.6448.81503.92332.75
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-55.24143.54219.6448.81503.92332.75
Total Liabilities & Stockholders Equity3,473.352,577.412,672.722,714.312,221.232,053.90
Book Value Per Share-0.481.261.850.414.292.83
Tangible Book Value Per Share-13.43-11.93-11.09-12.85-2.22-3.83
Full-Time Employees---423--
Price to Book Ratio-212.4142.24155.9515.7025.9213.29
Return on Assets17.0517.8614.3312.9927.4527.70
Return on Equity216.38173.6799.40153.59124.50179.14
Return on Invested Capital8.5511.056.96-6.3913.448.97
Quick Ratio3.602.312.333.661.377.01
Current Ratio3.882.712.764.661.598.36

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income247.05229.91150.05-141.59175.22165.16
Depreciation34.2033.9733.7326.6820.4220.50
Other Funds (Non Cash)19.2019.6719.07360.1413.8813.16
Funds from Operations295.30284.46206.28228.46236.88191.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-37.03-43.56-26.20-9.43-58.28-92.02
Cash from Operating Activities258.27240.89180.08219.03178.6099.71
Capital Expenditures-3.05-4.17-3.74-1.43-3.03-1.56
Net Assets From Acquisitions0.000.000.00-1,013.740.000.00
Sale of Fixed Assets and Businesses0.000.000.710.000.000.00
Purchase or Sale of Investments24.00-58.490.15273.38204.6486.35
Purchase of Investments-0.00-111.76-8.850.00-4.96-102.76
Sale Or Maturity of Investments24.0053.279.00273.38209.59189.11
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities20.95-62.66-2.88-741.79201.6184.79
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-44.47-327.860.004.15-22.40-302.29
Repurchase of Common Pref Stock-67.27-332.730.000.00-38.88-303.49
Sale of Common Pref Stock22.804.870.004.1516.481.20
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net632.120.000.00235.370.000.00
Change in Long Term Debt632.120.000.00235.370.000.00
Issuance of Long Term Debt1,471.880.000.001,465.060.000.00
Reduction of Long Term Debt-839.760.000.00-1,229.690.000.00
Net Financing Active Other Cash Flow0.001.61-1.610.000.003.32
Other Financing Activities Uses0.001.61-1.610.000.003.32
Cash from Financing Activities587.64-326.25-1.61239.51-22.40-298.97
Net Change in Cash866.86-148.02175.59-283.24357.80-114.47
Free Cash Flow255.22236.72176.34217.60175.5798.15
Price to Free Cash Flow15.2811.7711.8912.2914.8911.95

Revenue breakdown

Bulk rHuPH202024: 86.33M 2025: 133.02M
Device Licensing and Development2024: 11.34M 2025: 16.86M
Device Partnered Products2024: 50.54M 2025: 48.81M
Event -based Development And Regulatory Milestone And Other Fees2024: 72.50M 2025: 47.00M
Proprietary Products Sales2024: 166.62M 2025: 194.61M
Royalty2024: 570.99M 2025: 867.84M
Sales-based milestone2024: 30.00M 2025: 70.00M
Upfront Fees2024: 27.00M 2025: 18.47M
Belgium2024: 84.01M 2025: 217.52M
Foreign, Other2024: 9.53M 2025: 33.33M
Japan2024: 18.94M 2025: 46.37M
Switzerland2024: 212.39M 2025: 276.41M
United States2024: 690.46M 2025: 822.98M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.10%13.7M112.8M2.28M
2026-10-1512.16%13.7M112.3M2.22M
2026-09-3013.62%15.3M112.3M2.16M
2026-09-1513.50%15.2M112.3M1.94M
2026-08-3113.26%14.9M112.3M2.00M
2026-08-1413.03%14.6M112.3M2.00M
2026-07-3112.49%14.0M112.3M1.85M
2026-07-1511.33%13.3M117.4M1.80M
2026-06-3011.27%13.2M117.4M1.72M
2026-06-1511.04%12.9M117.3M1.62M
2026-05-2911.62%13.6M117.4M1.61M
2026-05-1511.41%13.4M117.4M1.70M
2026-04-3012.27%14.4M117.2M1.72M
2026-04-1512.16%14.3M117.2M1.74M
2026-03-3112.05%14.0M116.5M1.88M
2026-03-1311.76%13.7M116.5M1.87M
2026-02-2711.58%13.5M116.5M2.07M
2026-02-1311.84%13.8M116.5M2.04M
2026-01-3011.66%13.5M115.9M2.21M
2026-01-1511.69%13.6M116.3M2.20M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call55.0043.7046.800.002.8960.000.000.981-0.0880.007
call60.0038.5041.800.002.5470.000.000.978-0.0860.008
call65.0033.7036.900.002.2670.000.000.974-0.0850.009
call70.0029.0031.900.001.9610.000.000.970-0.0830.011
call75.0023.8026.900.001.6710.000.000.965-0.0800.012
call80.0019.2021.900.001.3940.000.000.958-0.0770.014
call85.0013.8016.200.000.9190.000.000.934-0.0900.020
call90.009.4011.6011.000.7873.001.000.912-0.0820.025
call95.005.107.5013.300.7711.000.000.684-0.2700.056
call1002.254.502.750.68422.004.000.535-0.2360.063
call1050.452.652.250.71241.000.000.362-0.2320.059
call1100.151.200.930.6738080.000.210-0.1720.046
call1150.001.650.070.85880.000.000.175-0.1940.041
call1200.051.550.571.0231282.000.153-0.2120.037
call1250.000.750.251.0322560.000.103-0.1620.028
call1300.000.750.361.1631,6580.000.094-0.1700.027
call1350.000.300.051.0611,0560.000.046-0.0900.015
call1400.000.950.051.1631,4000.000.043-0.0920.014
call1450.002.150.921.2536.000.000.040-0.0950.014
call1500.000.950.951.35141.000.000.038-0.0970.013
call1550.002.150.551.4381.000.000.036-0.0990.012
call1600.002.150.201.5220.000.000.034-0.1010.012
call1650.000.950.001.6010.000.000.033-0.1030.012
put55.000.002.150.051.9971.000.00-0.019-0.0820.007
put60.000.002.150.001.7400.000.00-0.022-0.0800.008
put65.000.002.200.001.5020.000.00-0.026-0.0770.009
put70.000.001.900.081.2805.000.00-0.030-0.0750.011
put75.000.001.500.001.0700.000.00-0.035-0.0720.012
put80.000.000.250.600.7425.000.00-0.022-0.0340.008
put85.000.001.200.100.7282.001.00-0.066-0.0810.020
put90.000.050.350.220.52719.002.00-0.088-0.0720.025
put95.000.053.100.900.87418.000.00-0.316-0.2600.056
put1001.003.902.500.64933.001.00-0.465-0.2250.063
put1055.407.006.590.6671,7951.00-0.638-0.2200.059
put1108.7011.309.060.77656.001.00-0.790-0.1590.046
put11513.4016.4012.900.9951770.00-0.825-0.1810.041
put12018.4021.2018.051.12540.000.00-0.847-0.1980.037
put12523.3026.4020.801.33425.000.00-0.897-0.1480.028
put13028.3031.4022.801.4847.000.00-0.906-0.1560.027
put13533.3036.4012.601.62338.000.00-0.954-0.0750.015
put14038.3041.500.001.7820.000.00-0.957-0.0770.014
put14543.3046.300.001.8480.000.00-0.960-0.0790.014
put15048.3051.400.001.9940.000.00-0.962-0.0800.013
put15553.3057.200.002.4060.000.00-0.964-0.0820.012
put16058.3061.9029.902.3581.000.00-0.966-0.0830.012
put16563.3066.800.002.3740.000.00-0.967-0.0840.012

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-084/A2026-05-05SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-023Initial statement of beneficial ownership of securities2026-09-28SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-308-KCurrent report2026-09-28SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-09-188-KCurrent report2026-09-17SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-168-KCurrent report2026-09-16SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-213Initial statement of beneficial ownership of securities2026-08-14SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-188-KCurrent report2026-08-14SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-028-KCurrent report2026-06-30SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10007.18M4
2026-09008.48M4
2026-08006.44M4
2026-0700278.04K2
2026-06004.03M5
2026-05003.54M4
2026-04003.23M3
2026-03005.43M5
2026-02003.85M3
2026-0100140.50K1
2025-12001.20M2
2025-11004.58M5

Institutional holders

Manager% owned
BlackRock, Inc.11.19%
TPG GP A, LLC8.43%
OFI INVEST ASSET MANAGEMENT5.73%
Focus Partners Wealth5.10%
ABSOLUTE INVESTMENT ADVISERS, LLC4.62%
VANGUARD CAPITAL MANAGEMENT LLC4.51%
VANGUARD PORTFOLIO MANAGEMENT LLC4.47%
STATE STREET CORP4.37%
RATIONAL ADVISORS, INC.4.31%
STATE OF WISCONSIN INVESTMENT BOARD3.43%

Funds

Fund% owned
Virtus Income & Growth Fund11.73%
Virtus Convertible Fund11.26%
AQR Diversified Arbitrage Fund10.24%
Miller Market Neutral Income Fund7.59%
NYLIM MacKay Convertible Fund7.47%
NYLIM VP MacKay Convertible Portfolio6.43%
Invesco Convertible Securities Fund6.32%
Putnam Convertible Securities Fund5.54%
Rational/Pier 88 Convertible Securities Fund4.31%
Miller Convertible Bond Fund4.22%

OakChart. HALO. Cached 15 minutes.